Literature DB >> 23708664

Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells.

P Cappello1, H Blaser2, C Gorrini2, D C C Lin3, A J Elia2, A Wakeham2, S Haider4, P C Boutros4, J M Mason3, N A Miller5, B Youngson5, S J Done6, T W Mak2.   

Abstract

Breast cancer is the most common solid tumor and the second most common cause of death in women. Despite a large body of literature and progress in breast cancer research, many molecular aspects of this complex disease are still poorly understood, hindering the design of specific and effective therapeutic strategies. To identify the molecules important in breast cancer progression and metastasis, we tested the in vivo effects of inhibiting the functions of various kinases and genes involved in the regulation/modulation of the cytoskeleton by downregulating them in mouse PyMT mammary tumor cells and human breast cancer cell lines. These kinases and cytoskeletal regulators were selected based on their prognostic values for breast cancer patient survival. PyMT tumor cells, in which a selected gene was stably knocked down were injected into the tail veins of mice, and the formation of tumors in the lungs was monitored. One of the several genes found to be important for tumor growth in the lungs was NIMA-related kinases 2 (Nek2), a cell cycle-related protein kinase. Furthermore, Nek2 was also important for tumor growth in the mammary fat pad. In various human breast cancer cell lines, Nek2 knockdown induced aneuploidy and cell cycle arrest that led to cell death. Significantly, the breast cancer cell line most sensitive to Nek2 depletion was of the triple negative breast cancer subtype. Our data indicate that Nek2 has a pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive and novel therapeutic target for this disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23708664     DOI: 10.1038/onc.2013.183

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  47 in total

1.  Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity.

Authors:  C Sakamoto; H Kohara; H Inoue; M Narusawa; Y Ogawa; L Hirose-Yotsuya; S Miyamoto; Y Matsumura; K Yamada; A Takahashi; K Tani
Journal:  Cancer Gene Ther       Date:  2017-01-13       Impact factor: 5.987

2.  Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2.

Authors:  Jia Wang; Peng Cheng; Marat S Pavlyukov; Hai Yu; Zhuo Zhang; Sung-Hak Kim; Mutsuko Minata; Ahmed Mohyeldin; Wanfu Xie; Dongquan Chen; Violaine Goidts; Brendan Frett; Wenhao Hu; Hongyu Li; Yong Jae Shin; Yeri Lee; Do-Hyun Nam; Harley I Kornblum; Maode Wang; Ichiro Nakano
Journal:  J Clin Invest       Date:  2017-07-24       Impact factor: 14.808

Review 3.  Targeting NEK2 as a promising therapeutic approach for cancer treatment.

Authors:  Yanfen Fang; Xiongwen Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

4.  NEK2 promotes proliferation, migration and tumor growth of gastric cancer cells via regulating KDM5B/H3K4me3.

Authors:  Yiwei Li; Lijuan Chen; Lixing Feng; Mengli Zhu; Qiang Shen; Yanfen Fang; Xuan Liu; Xiongwen Zhang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

5.  Nanostructured lipid carriers loaded with tributyrin as an alternative to improve anticancer activity of all-trans retinoic acid.

Authors:  Elton Luiz Silva; Guilherme Carneiro; Priscila Albuquerque Caetano; Gisele Goulart; Daniel Ferreira Costa; Elaine Maria de Souza-Fagundes; Dawidson Assis Gomes; Lucas Antônio Miranda Ferreira
Journal:  Expert Rev Anticancer Ther       Date:  2015-02       Impact factor: 4.512

6.  Abnormal expression of Nek2 in pancreatic ductal adenocarcinoma: a novel marker for prognosis.

Authors:  Zhen Ning; Aman Wang; Jinxiao Liang; Jiwei Liu; Tao Zhou; Qiu Yan; Zhongyu Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 7.  Therapeutic melting pot of never in mitosis gene a related kinase 2 (Nek2): a perspective on Nek2 as an oncology target and recent advancements in Nek2 small molecule inhibition.

Authors:  Brendan Frett; Robert V Brown; Mingliang Ma; Wenhao Hu; Haiyong Han; Hong-yu Li
Journal:  J Med Chem       Date:  2014-02-25       Impact factor: 7.446

Review 8.  Non-mammalian models of multiple endocrine neoplasia type 2.

Authors:  Tirtha K Das; Ross L Cagan
Journal:  Endocr Relat Cancer       Date:  2018-02       Impact factor: 5.678

9.  Clinical significance and prognostic value of Nek2 protein expression in colon cancer.

Authors:  Lei Lu; Xiaofeng Zhai; Ronghua Yuan
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

10.  LIN9 and NEK2 Are Core Regulators of Mitotic Fidelity That Can Be Therapeutically Targeted to Overcome Taxane Resistance.

Authors:  Melyssa S Roberts; Jennifer M Sahni; Morgan S Schrock; Katrina M Piemonte; Kristen L Weber-Bonk; Darcie D Seachrist; Stefanie Avril; Lindsey J Anstine; Salendra Singh; Steven T Sizemore; Vinay Varadan; Matthew K Summers; Ruth A Keri
Journal:  Cancer Res       Date:  2020-02-13       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.